Skip to main content Accessibility help
×
Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-28T13:22:38.658Z Has data issue: false hasContentIssue false

Debate 19A - What is the Optimal Therapeutic Option for Platinum-resistant Recurrent Ovarian Cancer

Single-agent Chemotherapy

from Section III - Ovarian Cancer

Published online by Cambridge University Press:  20 July 2023

Dennis S. Chi
Affiliation:
Memorial Sloan-Kettering Cancer Center, New York
Nisha Lakhi
Affiliation:
Richmond University Medical Center, Staten Island
Nicoletta Colombo
Affiliation:
University of Milan-Bicocca
Get access

Summary

Treatment of platinum-resistant ovarian cancer poses a challenge to oncologists, as this type of cancers is incurable, and no optimal or standard treatment exists. The available cytotoxic drugs show similar progression-free survival and overall survival rates; therefore, oncologists should consider each case individually and assess not only efficacy but also the possible impact on patient’s quality of life and risks of toxicity. This chapter explores the different treatment options for platinum-resistant ovarian cancer.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

McMullen, M, et al. New approaches for targeting platinum-resistant ovarian cancer. Semin Cancer Biol 2020;2020:S1044–579X(20)30186–3. https://doi.org/10.1016/j.semcancer.2020.08.013Google Scholar
Pujade-Lauraine, E, et al. Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives. J Clin Oncol 2019;37(27):24372448. https://doi.org/10.1200/JCO.19.00194CrossRefGoogle ScholarPubMed
Lee, JM, et al. New strategies in ovarian cancer treatment. Cancer 2019;125(Suppl. 24):46234629. https://doi.org/10.1002/cncr.32544CrossRefGoogle ScholarPubMed
Poveda, AM, et al. Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial. J Clin Oncol 2014;33:38363838.CrossRefGoogle Scholar
Oronsky, B, et al. A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer. Med Oncol 2017;34(6):103. https://doi.org/10.1007/s12032-017-0960-zCrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×